Mice that have been genetically modified to be prone to tumours are thought to be poor models of sporadic cancer. This problem can be tackled with a new generation of modified mice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hanahan, D. & Weinberg, R. A. Cell 100, 57–70 (2000).
Kinzler, K. W. & Vogelstein, B. Cell 87, 159–170 (1996).
Tuveson, D. A. & Jacks, T. Oncogene 18, 5318–5324 (1999).
Johnson, L. et al. Nature 410, 1111–1116 (2001).
Garcia, S. B., Park, H. S., Novelli, M. & Wright, N. A. J. Pathol. 187, 61–81 (1999).
Land, H., Chen, A. C., Morgenstern, J. P., Parada, L. F. & Weinberg, R. A. Mol. Cell. Biol. 6, 1917–1925 (1986).
Deng, G., Lu, Y., Zlotnikov, G., Thor, A. D. & Smith, H. S. Science 274, 2057–2059 (1996).
Thrane, E. V. et al. Exp. Lung Res. 23, 35–49 (1997).
Sauer, B. Methods 14, 381–392 (1998).
Contag, C. H., Jenkins, D., Contag, P. R. & Negrin, R. S. Neoplasia 2, 41–52 (2000).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Berns, A. Improved mouse models. Nature 410, 1043–1044 (2001). https://doi.org/10.1038/35074238
Issue Date:
DOI: https://doi.org/10.1038/35074238
This article is cited by
-
Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development
Immunologic Research (2011)
-
Mouse models in oncogenesis and cancer therapy
Clinical and Translational Oncology (2006)
-
‘Designer’ tumors in mice
Oncogene (2004)
